Blood cancers

Brentuximab vedotin is PBS listed for CTCL

The PBS will subsidise brentuximab vedotin (Adcetris) for treatment of cutaneous T-cell lymphomas (CTCL) from 1 April. The listing is expected to benefit about 60 patients per year who would otherwise pay up to $300,000 a year for this treatment. The subsidy was recommended by the Pharmaceutical Benefits Advisory Committee (PBAC), which concluded in November ...

Already a member?

Login to keep reading.

© 2021 the limbic